Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Kevin Hickey has joined Acerus Pharmaceuticals as senior vice president of U.S. commercial. Prior to this appointment, Hickey was senior director of marketing of sleep medicine at Jazz Pharmaceuticals.
Adverum Biotechnologies has named Christopher Morrison its newest vice president of process science. Morrison was most recently senior director of biopharmaceutical development at Apic Bio.
Pharma company Aprecia has appointed Kathi Rinesmith to senior vice president of regulatory affairs. Rinesmith was most recently director of global regulatory affairs and global pharmacovigilance at Adare Pharmaceuticals.
Reshma Rangwala has been appointed chief medical officer of Aravive. Previously, Rangwala was vice president of medical at Genmab.
David Bennett, former vice president of business development at Syneos Health Commercial Solutions, has been named chief operations officer of Atlantic Healthcare.
Bayer has extended CEO Werner Baumann’s contract from 2021 to the end of April 2024. Baumann has been with the company since 1988.
Recently launched biotech company Cellinta Limited has named Soraya Bekkali as its CEO. Bekkali was most recently CEO and director of the board of Gyroscope Therapeutics.
John Wagner, who most recently served as venture partner of Foresite Capital, has been named chief medical officer of Cygnal Therapeutics.
Robert Cobuzzi has been named CEO of Diffusion Pharmaceuticals. Cobuzzi most recently served as president of Endo Ventures.
Biotech company EQRx has named Rona Anhalt as chief people officer, Christian Antoni as chief development officer, Eric Hedrick as chief physician executive and Daniel Hoey as chief of technical operations. Before these appointments, Anhalt served as corporate vice president of human resources at Celgene, Antoni was senior vice president of global development at LEO Pharma, Hedrick was chief advisor to BeiGene and Hoey was senior vice president of global supply chain at Teva Pharmaceuticals.
Cooper Anderson has been named chief financial officer of Florence Healthcare. Anderson most recently served as chief financial officer at Acuity.
Forma Therapeutics has appointed Fitzroy Dawkins, former executive director of oncology drug development at Incyte, to the role of president of clinical development. Forma has also named Ruth du Moulin vice president of medical affairs. Most recently, Moulin served as vice president of medical affairs and head of global oncology medical communications at Takeda Oncology’s global business unit.
Denis Bedoret has been named CEO of Imcyse. Prior to this role, Bedoret served as CEO of contract development and manufacturing organization MaSTherCell.
Mike Spigarelli has been named chief medical officer of Lumen Bioscience. Spigarelli was most recently vice president of medical affairs of Immucor.
Michael Mullette has been appointed a managing director of Moderna’s new Canadian subsidiary. Mullette will continue to serve as vice president of market access, a role he assumed at Moderna in August 2020.
Olema Oncology has announced several new staff appointments, including Shane Kovacs to chief operating officer/chief financial officer, Kinney Horn to chief business officer, John Moriarty to executive vice president and chief legal officer, and Pamela Klein to chief medical officer. Prior to these appointments, Kovacs served as chief business and financial officer of BlueRock Therapeutics. Additionally, Horn was entrepreneur in residence at EcoR1 Capital, Moriarty served as executive vice president at Portola Pharmaceuticals and Klein was previously an independent biotech/pharma consultant.
Ed Rock has been appointed chief medical officer of Partner Therapeutics. Formerly, Rock served as clinical project leader and vice president of clinical research at MacroGenics.
Prilenia Therapeutics has named Henk Schuring as chief regulatory and commercialization officer. Formerly, Schuring was vice president and head of the rare nephrological diseases business and the rare neurological diseases business units at Sanofi Genzyme.
Robert Doebele, who cofounded Rain Therapeutics in 2017, has recently been named executive vice president and chief scientific officer of the company.
Yann Mazabraud has been named executive vice president and head of international at Rhythm Pharmaceuticals. Most recently, Mazabraud was chief commercial officer and head of international at Trevi Therapeutics.
Russell Skibsted has been named executive vice president, chief financial officer and chief business officer of Rockwell Medical. Prior to this new role, Skibsted was chief financial officer of AgeX Therapeutics.
Bo Hansen has been appointed to CEO of Scandion Oncology, taking the reins from Nils Brünner who has assumed the role of chief scientific officer. Most recently, Hansen was president and CEO of Genevant Sciences.
Sensyne Health has appointed Michael Macdonnell, current director of global deployment at Google Health, to the role of chief operating officer.
Martin Madaus has been appointed chief operations officer of Sherlock Biosciences. Most recently, Madaus was interim CEO and executive chairman of Ultivue and Emulate Bio.
Mark Rothera has been named president and CEO of Silence Therapeutics. Most recently, Rothera was CEO of Orchard Therapeutics.
David Hava has been appointed to the role of chief scientific officer at Synlogic. Most recently, Hava was chief scientific officer of Metera Pharmaceuticals.
Targazyme has appointed Jim Caggiano to lead the company as its newest CEO. Caggiano is the former president of Valeant.
Tizona Therapeutics has appointed Christine O’Brien to CEO. O’Brien was most recently chief operating officer at the company.
Clinical-stage biotech company VectivBio has appointed Nader Youssef to senior vice president and head of global clinical development and medical affairs. Most recently, Youssef served as vice president of clinical development at Passage Bio and chief medical officer at Nutrinia.
Jeffrey Silber has been named chief medical officer of Vedanta Biosciences. Previously, Silber was senior vice president of global development of EMD Serono.
Charles Hugh-Jones has been appointed CEO of Volastra Therapeutics. Hugh-Jones most recently served as global chief medical officer of Allergan.
Keith Reynolds has been hired by Welldoc to fill the role of chief operating officer. Reynolds most recently served as vice president of enterprise health plans and market strategy at CVS Health.
Zealand Pharma has named Danilo Verge, former AstraZeneca vice president, to be head of global medical affairs. David Kendall has also been hired by Zealand Pharma to assume the position of senior global medical adviser for metabolism. Kendall recently served as chief medical officer of MannKind.